Spyre Therapeutics, Inc. Common Stock (SYRE) Financials
Key financial figures for Spyre Therapeutics, Inc. Common Stock (Q3 2026).
Q3 2026 net loss widened to $96.1M from $11.2M a year earlier as R&D rose to $89.2M; pro forma cash of $1.47B extends runway into the second half of 2029. Net loss was $96.1M, or $0.94 per common share, versus $11.2M, or $0.15 per share, in Q3 2025. The prior-year quarter included $45.7M of total other income, driven mainly by changes in the fair value of the CVR liability. R&D expense was $89.2M versus $45.2M a year earlier, which the company attributes primarily to higher manufacturing costs and clinical trial expenses. G&A was $16.6M versus $11.6M on higher headcount and professional fees. On the outlook: Management expects the pro forma cash of $1,467.9 million as of September 30, 2026 to fund operations into the second half of 2029; SKYLINE Part B induction topline data are expected in Q3 2027, SKYLIGHT Week 16 topline results in late 2027 or early 2028, and a pivotal anti-TL1A monotherapy program in hidradenitis suppurativa is planned to start in 2027. Figures are for Q3 2026, as Spyre Therapeutics Inc. reported them.
- Revenue
- $0
- Net Income
- -$96M
- EPS
- $-0.94
- Total Assets
- $1.1B
- Operating Cash Flow
- -$77M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $0 | -$96M | -$0.94 | -$77M | |
| Q2 FY2026 | $0 | -$36M | -$0.36 | -$70M | |
| Q1 FY2026 | $0 | -$69M | -$0.74 | -$57M | |
| Q4 FY2025 | $90M | -$63M | -$0.70 | -63.18% | -$45M |
| Q3 FY2025 | $0 | -$11M | -$0.15 | -$37M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$155M | -$1.98 | -$169M | |
| FY2024 | $0 | -$208M | -$3.18 | -$157M | |
| FY2023 | $886K | -$339M | -$46.15 | -27347.97% | -$100M |
Frequently asked questions
What was Spyre Therapeutics Inc.'s revenue last quarter?
Spyre Therapeutics Inc. reported revenue of $0.00 for Q3 FY2026.
Is Spyre Therapeutics Inc. profitable?
Not in its most recent reported period. Spyre Therapeutics Inc. reported a net loss of $96.1 million for Q3 FY2026.
How much free cash flow did Spyre Therapeutics Inc. generate?
Spyre Therapeutics Inc. generated free cash flow of -$77.5 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Spyre Therapeutics, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.